Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy
Jana Samarin, Hana Nůsková, Piotr Fabrowski, Mona Malz, Eberhard Amtmann, Minerva Taubert, Daniel Pastor‐Flores, Daniel N. Kazdal, Roman Kurilov, Nicole de Vries, Hannelore Pink, Frank H. Deis, Johanna Hummel-Eisenbeiss, Lisa Renz, Kamini Kaushal, , Nikolas Gunkel
The paper shows that activating the NRF2 pathway can safely increase the dose of TXNRD1 inhibitors in SCLC treatment without harming healthy tissues.
Nature Communications · Apr 11, 2026Peer-reviewedCancer Biology